Levetiracetam Heumann (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. This binding modulates vesicle exocytosis, reduces calcium‑dependent release of excitatory neurotransmitters, and stabilises neuronal membranes, thereby lowering neuronal excitability and interrupting seizure propagation.

The dosage of Levetiracetam Heumann is determined by the prescribing clinician based on the patient’s age, weight, renal function and seizure type. Only a qualified healthcare professional should set the appropriate dose and administration schedule.

Safety data for Levetiracetam Heumann in pregnancy are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the possible risk to the fetus. Breastfeeding mothers should consult their physician, as the drug is excreted in breast milk.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain logistics if required) and any necessary import documentation.

Levetiracetam has a unique mechanism targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproate. It generally has fewer drug‑enzyme interactions, a relatively favourable side‑effect profile, and can be used as add‑on therapy. Choice of therapy depends on seizure type, patient comorbidities and tolerability.

Levetiracetam Heumann should be stored at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and do not freeze or shake the solution. Maintaining the cold‑chain ensures product stability and potency.

Levetiracetam Heumann is administered intravenously by a qualified healthcare professional. The solution is typically infused over a short period, following the dosing instructions provided by the prescriber. Intravenous administration allows rapid achievement of therapeutic plasma concentrations.

Serious risks include severe allergic reactions such as anaphylaxis, life‑threatening skin conditions like Stevens‑Johnson syndrome, blood dyscrasias (e.g., neutropenia), hepatic dysfunction, and emergence of suicidal thoughts or behavior. Patients should be monitored closely for any of these events, and treatment should be discontinued if they occur.

Levetiracetam Heumann is contraindicated in patients with known hypersensitivity to levetiracetam or any of the excipients in the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled psychiatric disorders, or those receiving live vaccines, as interactions may reduce vaccine efficacy.